Diagnostisch Therapeutisches Zentrum Berlin (DTZ) has become the first facility worldwide to treat a patient using Elekta Evo, an AI-powered CT-linac system designed for advanced, personalized cancer care.

The Elekta Evo system combines Iris high-definition imaging and Elekta ONE Online software to enhance image clarity and streamline treatment workflows. According to Dr. Matthias Lampe, radiation oncologist and partner at DTZ, these capabilities significantly improve tumor visualization and real-time treatment planning.

“With Iris, CBCT image quality has improved significantly thanks to AI-enhanced image reconstruction,” Lampe said. “This gives us greater confidence and saves time, improving not only the quality of treatment but also patient comfort.”
Evo’s adaptive radiation therapy allows clinicians to tailor treatments to individual patient needs, offering both online and offline plan adaptation. This flexibility is particularly valuable for addressing complex cases or adjusting to anatomical changes during therapy.

DTZ, which already operates five state-of-the-art linear accelerators, is known for integrating cutting-edge technologies into its oncology practice. Gustaf Salford, Elekta’s president and CEO, highlighted DTZ’s role as a longtime partner. “Evo is facilitating personalized radiotherapy for cancer patients,” he said. “We look forward to seeing more facilities adopt this innovative system in the coming months.”

Elekta Evo has received CE marking and is pending FDA clearance in the United States.

CT Homepage